Sit Investment Associates’s Celldex Therapeutics CLDX Stock Holding History

Sit Investment Associates’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-983	Closed	-$36K	–	661
2017 Q2	$36K	Sell	983 -65	-6%	-$2.88K	﹤0.01%	500
2017 Q1	$57K	Sell	1,048 -570	-35%	-$29.7K	﹤0.01%	496
2016 Q4	$86K	Hold	1,618	–	–	﹤0.01%	468
2016 Q3	$98K	Hold	1,618	–	–	﹤0.01%	412
2016 Q2	$107K	Sell	1,618 -2,600	-62%	-$165K	﹤0.01%	408
2016 Q1	$239K	Hold	4,218	–	–	﹤0.01%	390
2015 Q4	$992K	Hold	4,218	–	–	0.02%	318
2015 Q3	$667K	Hold	4,218	–	–	0.01%	352
2015 Q2	$1.6M	Hold	4,218	–	–	0.03%	271
2015 Q1	$1.76M	Sell	4,218 -2,747	-39%	-$983K	0.03%	253
2014 Q4	$1.91M	Sell	6,965 -536	-7%	-$133K	0.03%	273
2014 Q3	$1.46M	Sell	7,501 -3,820	-34%	-$832K	0.03%	300
2014 Q2	$2.77M	Hold	11,321	–	–	0.05%	269
2014 Q1	$3M	Buy	11,321 +5,567	+97%	+$2.13M	0.05%	251
2013 Q4	$2.09M	Buy	5,754 +1,462	+34%	+$563K	0.04%	284
2013 Q3	$2.28M	Buy	+4,292	New	+$1.47M	0.04%	258

Other funds holding CLDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Sit Investment Associates's CLDX Position: Q3 2017 in Review

Sit Investment Associates sold out of Celldex Therapeutics (CLDX) in Q3 2017, closing a stake of 983 shares — an estimated $36K sold.

Sit Investment Associates first reported a position in CLDX in Q3 2013 and held it in 16 quarters. The position peaked at $3M in Q1 2014. 129 funds tracked by Wall St. Rank hold CLDX as of Q3 2017.

Sit Investment Associates reported no remaining Celldex Therapeutics position as of Q3 2017 after selling out during the quarter.
Sit Investment Associates sold 983 Celldex Therapeutics shares in Q3 2017, an estimated $36K.
Sit Investment Associates first reported a position in Celldex Therapeutics in Q3 2013 and held it in 16 quarters.
Sit Investment Associates's Celldex Therapeutics position peaked at $3M in Q1 2014.
129 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2017.

Based on Sit Investment Associates's 13F filing for Q3 2017, filed 18 Oct 2017.